Sinovac reports wider Q1 losses on higher expenses, but increases sales Print E-mail
By Olivia D'Orazio-Proactiveinvestors.com   
Saturday, 14 May 2011 13:29

Vaccine maker Sinovac Biotech (NASDAQ:SVA) reported wider first quarter net and operating losses, despite an increase in revenue from the year-ago period.


For the first three months of 2011, the China-based biopharmaceutical company disclosed a wider net loss attributable to stockholders of $2.8 million, or $0.05 per share, comparable to the year ago period's net loss of $0.3 million, or $0.01 per share.

Sinovac did, however, report an increase in sales, up 5.3% to $4.7 million from $4.4 million last year. The company said that sales would have increased by 50% had it not been for the H1N1 flu scare that caused a spike in the sale of its influenza vaccines in the year-ago period.

Gross margins slid down to 66.1% from 80.1% a year earlier, due to lower plant utilization as reduced demand caused the company to scale back production.

The addition of new sales personnel and the continued development of several vaccinations caused a 47.7% increase in the company's operating expenses to $6.5 million. This also contributed to a bigger operating loss of $3.4 million from $0.8 million in the first quarter of 2010.

"We are pleased to see the R&D projects moving forward smoothly. The Phase I trial for our proprietary EV71 vaccine (for hand, foot and mouth disease) is progressing well with the inoculations in the young children completed and infants to be completed in the coming weeks," said president and CEO, Dr. Weidong Yin.

Sinovac is also entering trial production for its mumps vaccination and expects its new animal rabies vaccine to launch next year.

The company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, seasonal influenza, bird flu and H1N1 influenza.

 

“Proactiveinvestors is a leading news organisation and event business with offices in New York, Sydney, Toronto and London. The Company is a publisher and is not registered with the US Securities Exchange Commission or Ontario Securities Commission. Please read our full terms and conditions herehttp://www.proactiveinvestors.com/pages/terms




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter